Epidemiological characteristics and diagnosis and treatment effect of rifampicin-resistant pulmonary tuberculosis (RR-PTB) in Guizhou province

Author:

Zhou Jian1,Li Jinlan2,Hu Yong1,Li Shijun1

Affiliation:

1. Guiyang Medical University

2. Guizhou Center for Disease Control and Prevention

Abstract

Abstract

Background Rifampicin-resistant pulmonary tuberculosis (RR-PTB) presents a significant threat to global public health security. China bears a substantial burden of RR-PTB cases globally, with Guizhou Province experiencing particularly alarming trends, marked by a continual increase in patient numbers. Understanding the population characteristics and treatment modalities for RR-PTB is crucial for mitigating morbidity and mortality associated with this disease. Methods We gathered epidemiological, diagnostic, and treatment data of all RR-PTB cases recorded in Guizhou Province from 2017 to 2023. Utilizing composition ratios as the analytical metric, we employed Chi-square tests to examine the spatiotemporal distribution patterns of RR-PTB patients and the evolving trends among different patient classifications over the study period. Results In our study, 3396 cases of RR-PTB were analyzed, with an average age of 45 years. The number of RR-PTB patients rose significantly from 176 in 2017 to 960 in 2023, peaking notably among individuals aged 23–28 and 44–54, with a rising proportion in the 51–80 age group (P < 0.001). Since 2021, there has been a notable increase in the proportion of female patients. While individuals of Han nationality comprised the largest group, their proportion decreased over time (P < 0.001). Conversely, the Miao ethnicity showed an increasing trend (P < 0.05). The majority of patients were farmers, with their proportion showing an upward trajectory (P < 0.001), while students represented 4.33% of the cases. Geographically, most patients were registered in Guiyang and Zunyi, with a declining trend (P < 0.001), yet household addresses primarily clustered in Bijie, Tongren, and Zunyi. The proportion of floating population patients gradually decreased, alongside an increase in newly treated patients and those without prior anti-tuberculosis therapy. Additionally, there was a notable rise in molecular biological diagnostic drug sensitivity (P < 0.001). However, the cure rate declined, coupled with an increasing proportion of RR-PTB patients lost to follow-up and untreated (P < 0.05). Conclusions Enhanced surveillance is crucial for detecting tuberculosis patients aged 23–28 and 44–54 years. The distribution of cases varies among nationalities and occupations, potentially influenced by cultural and environmental factors. Regional patterns in RR-PTB incidence suggest tailored prevention and control strategies are necessary. Despite molecular biology advances, challenges persist with low cure rates and high loss to follow-up. Strengthening long-term management, resource allocation, and social support systems for RR-PTB patients is essential.

Publisher

Research Square Platform LLC

Reference67 articles.

1. World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023.

2. Jiang H, Liu MY, Zhang YJ. Study on the Change regularity of Tuberculosis epidemic in China from 2005 to 2016// Compilation of papers of the 33DR National Academic Conference of China Tuberculosis Prevention Association and China Tuberculosis Science and Technology AwaDR Presentation Conference. Qingdao: China National Tuberculosis Association, Chongqing Zhifei Biological Products Co., LTD., 2021:176–177.

3. Yang X. Analysis of national tuberculosis epidemic characteristics and multi-regional incidence prediction from 2004 to 2014. Lanzhou: Lanzhou University; 2017.

4. Lu LP. Statistical analysis of the distribution characteristics of tuberculosis incidence in China. Lanzhou: Lanzhou University of Finance and Economics; 2019.

5. Yang LJ. Study on spatial distribution characteristics and influencing factors of tuberculosis. Beijing: Chinese Center for Disease Control and Prevention; 2020.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3